Wells Fargo Maintains Overweight on Agilon Health, Lowers Price Target to $16
Portfolio Pulse from Benzinga Newsdesk
Wells Fargo analyst Stephen Baxter has maintained an Overweight rating on Agilon Health (NYSE:AGL) but has reduced the price target from $23 to $16.
November 13, 2023 | 2:47 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Agilon Health's Overweight rating is maintained by Wells Fargo, but the price target is lowered from $23 to $16, indicating a potential downside according to the analyst's view.
The reduction in price target by Wells Fargo suggests that they see less upside potential for Agilon Health, which could lead to a negative short-term reaction in the stock price. However, maintaining the Overweight rating implies the analyst still sees the company as a good investment in the longer term.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100